Beta-lactam and Beta-lactamase Inhibitor Market to Grow at 1.9% CAGR by 2030

The widespread infectious diseases coupled with the growth in consumption of inhibitor drugs among the population promotes the growth of the Beta-lactam and Beta-lactamase inhibitor market.

The Beta-lactam and Beta-lactamase Inhibitor Market is expected to grow at a CAGR of 1.9% from 2020-2030, according to a new research report by Next Move Strategy Consulting.

Beta-lactam inhibitors fall under a drug class of antibiotic agents that help fight against bacterial infections and protozoa infections. Beta-lactam inhibitors either kill the bacteria directly or restrict it from multiplying. Beta-lactamase Inhibitors fall under a class of drugs that restrict the activity of beta-lactamase enzymes and limit the degradation of beta-lactam. Some examples of beta-lactam inhibitors are penicillin, cephalosporin etc.

According to the report, the rise in consumption of such beta-lactam and beta-lactamase inhibitors combined with the widespread presence of infectious diseases are among the major factors that promote the beta-lactam and beta-lactamase inhibitor market growth.

The global beta-lactam and beta-lactamase inhibitors market share has been segmented on the basis of type, route of administration, patient type, application/indication (disease level) and end user (healthcare setting). On the basis of type, the market is categorized into individual beta-lactum antibiotics and beta-lactum/beta-lactamase inhibitor combination. On the basis of route of administration, the market is segmented into oral administration, parental administration and other routes. On the basis of patient type, the market is segmented into adult patients and pediatric patients. On the basis of application/indication (disease level), the market is segmented into gynecological infections, intrabdominal infections, intraoperative prophylaxis,respiratory infections, skin and soft tissue infections (SSTI), urinary tract infections (UTI), bloodstream infections (BSI) and other infections. On the basis of end user (heathcare setting), the market is segmented into academic institutions, clinics, hospitals and research laboratories.in terms of geography, the market is categorized into North America, Europe, Asia Pacific and RoW.

At present, the North American region holds the highest market size & share in the beta-lactam and beta-lactamase inhibitor market because of developed health infrastructure and technology. Due to the growth in consumption of beta-lactam and beta-lactamase inhibitors in the Asia Pacific region, this region is predicted to show rapid market growth.

According to the report, some of the key players in the market are Alkem Laboratories Ltd., Aurobindo Pharma, Cipla Inc., Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Lupin Ltd., Meiji Holdings Co. Ltd., Merck & Co. Inc., Pfizer Inc., Sandoz International GmbH (Novartis), Shionogi & Co., Ltd., Sun Pharmaceutical Industries Ltd., Taj Pharmaceuticals Ltd.,Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Viatris (formerly Mylan N.V.), Zeelab Laboratories Ltd., Zentiva Group B.V.,and Zydus Lifesciences Limited (Cadila Healthcare) and others.

Key Insights from the Beta-lactam and Beta-lactamase Inhibitors Market Report:

• Current emerging trends and opportunities are extensively analysed in the Beta-Lactam and Beta-lactamase Inhibitor market report.

• The forecast of the Beta-Lactam and Beta-lactamase Inhibitor market comes along with additional information associated with opportunities, restrains and key drivers in the market. 

Get a free sample of the Beta-Lactam and Beta-lactamase Inhibitor market report

About Next Move Strategy Consulting

Next Move Strategy Consulting is an independent and trusted third-platform market intelligence provider, committed to deliver high quality, market research reports that help multinational companies to triumph over their competitions and increase industry footprint by capturing greater market share. Our research model is a unique collaboration of primary research, secondary research, data mining and data analytics.

We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicate as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solutions that ranges from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.

For more insights, browse reports